ArticleRisk analysis : an official publication of the Society for Risk Analysis2017
The World Health Organization Measles Programmatic Risk Assessment Tool-Romania, 2015.
Article in Risk analysis : an official publication of the Society for Risk Analysis, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 25 citations in OpenAlex.
- Article
- Effectiveness of Group and Individual Counselling Interventions on COVID-19 Vaccination Intention Among Industrial Employees in Romania.Patient preference and adherence · 2025Article
- Assessing measles risk transmission in Iran: a utilization of the World Health Organization's programmatic risk assessment tool,2022.BMC infectious diseases · 2024Article
- Suboptimal MMR Vaccination Coverages-A Constant Challenge for Measles Elimination in Romania.Vaccines · 2024Article
- [Stratification of risk areas for measles transmission: a systematic reviewEstratificación de las zonas de riesgo de transmisión del sarampión: revisión sistemática].Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Mapping priority areas for measles surveillance: stratifying reintroduction and transmission risk in Rio de Janeiro, Brazil.Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Subacute myoclonic measles encephalitis - An opportunistic HIV-associated infection.Frontiers in cellular neuroscience · 2023Article
- Evolving measles status and immunization policy development in six European countries.Human vaccines & immunotherapeutics · 2022Review
- A review of toolkits and case definitions for detecting enteric fever outbreaks in Asian and African countries from 1965-2019.Journal of global health · 2021Review
- A rapid risk analysis tool to prioritise response to infectious disease outbreaks.BMJ global health · 2020Article
- Phylogenetic and Epidemiological Analysis of Measles Viruses in Shenzhen, China from January 2015 to July 2019.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Article
- Characterisation of measles after the introduction of the combined measles-mumps-rubella (MMR) vaccine in 2004 with focus on the laboratory data, 2016 to 2019 outbreak, Romania.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2019Article
- The spatial analysis of annual measles incidence and transition threat assessment in Iran in 2016.Medical journal of the Islamic Republic of Iran · 2019Article
- Estimation of measles risk using the World Health Organization Measles Programmatic Risk Assessment Tool, Iran.Heliyon · 2018Article
- Monitoring of Surveillance Quality Indicators of Measles in Iranian Districts: Analysis of Measles Surveillance System 2014-2016.Journal of research in health sciences · 2018Article
- A Risk Analysis Approach to Prioritizing Epidemics: Ebola Virus Disease in West Africa as a Case Study.Risk analysis : an official publication of the Society for Risk Analysis · 2018Article
- Measles and rubella elimination: learning from polio eradication and moving forward with a diagonal approach.Expert review of vaccines · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 5 countries.
Funding
Abstract
Despite global improvement in annual measles incidence and mortality since 2000, progress toward elimination goals has slowed. The World Health Organization (WHO) European Region (EUR) established a regional goal for measles and rubella elimination by 2015. Romania is one of 13 EUR countries in which measles remains endemic. To identify barriers to meeting programmatic targets and to aid in prioritizing efforts to strengthen measles elimination strategy implementation, the WHO and U.S. Centers for Disease Control and Prevention developed a measles programmatic risk assessment tool that uses routinely collected data to estimate district-level risk scores. The WHO measles programmatic risk assessment tool was used to identify high-risk areas in order to guide measles elimination program activities in Romania. Of the 42 districts in Romania, 27 (64%) were categorized as very high or high risk. Many of the very-high-risk districts were clustered in the western part of the country or were clustered around the capital Bucharest in the southeastern part of the country. The overall risk scores in the very-high-risk districts were driven primarily by poor surveillance quality and suboptimal population immunity. The measles risk assessment conducted in Romania was the first assessment to be completed in a European country. Annual assessments using the programmatic risk tool could provide valuable information for immunization program and surveillance staff at the national level and in each district to guide activities to enhance measles elimination efforts, such as strengthening routine immunization services, improving immunization campaign planning, and intensifying surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.